Oncology Partnering Agreements in Pharma, Biotech and Diagnostics

Summary

The Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the oncology partnering agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery, preclinical or clinical whereby the licensee obtains a right or an option right to license the licensors oncology technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, licensing of outcomes and often retention by the licensor of co-promotion rights.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 900 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of oncology dealmaking since 2000. The chapter includes numerous case studies to enable understanding of oncology dealmaking as well as specific components such a co-promotion and option rights.
Chapter 3 provides an overview of the trends in oncology dealmaking since 2000.

Chapter 4 provides a review of the leading oncology deals since 2000. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of oncology contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of oncology partnering deals signed and announced since 2003, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific oncology therapy focus. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2000.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies, candidate compounds and products.

Key benefits
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:

• In-depth understanding of oncology deal trends since 2000
• Analysis of the structure of oncology agreements with numerous real life case studies
• Comprehensive access to over 900 actual oncology contracts entered into by the world's biopharma companies*
• Detailed access to actual oncology contracts enter into by the leading fifty bigpharma companies*
• Insight into the terms included in a oncology agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

*Subject to being published via regulatory requirements of the Securities Exchange Commission.
Report scope

Oncology Partnering Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the oncology trends and structure of deals entered into by leading biopharma companies worldwide.

• Trends in oncology dealmaking in the biopharma industry since 2000
• Analysis of oncology deal structure
• Case studies of real-life oncology deals
• Access to over 900 oncology contract documents
• The leading oncology deals by value since 2000
• Most active oncology dealmakers since 2000
• The leading oncology partnering resources

In Oncology Partnering Agreements in Pharma, Biotech and Diagnostics, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific oncology target

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for over 900 oncology deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise oncology rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Contents

Chapter 1 – Introduction

Chapter 2 – Overview of oncology dealmaking
2.1. Introduction
2.2. The anatomy of oncology partnering
2.2.1. The anatomy of an oncology deal
2.2.1.a. Case study 1: Celgene – Array Biopharma – September 2007
2.2.1.b. Case study 2: Merck – Ariad – July 2007
2.2.1.c. Case study 3: UCB – ImClone – August 2005
2.3. Typical partnering terms
2.3.1. Headline deal values
2.3.2. Upfront payments
2.3.3. Milestone payments
3.3.4. Royalties

Chapter 3 – Trends in oncology dealmaking
3.1. Introduction
3.2. Oncology partnering over the years
3.3. Most active oncology dealmakers
3.4. Bigpharma oncology dealmaking activity
3.5. Bigpharma not active in oncology
3.6. Oncology partnering by stage of development
3.7. Oncology partnering by deal type
3.7.1. Co-promotion oncology partnering
3.7.2. Option and evaluation oncology partnering
3.8. Oncology partnering by disease type
3.8.1. Trends in broad focus oncology partnering

Chapter 4 – Leading oncology deals
4.1. Introduction
4.2. Top oncology deals by value
4.3. Top oncology involving bigpharma

Chapter 5 – Bigpharma oncology deals
5.1. Introduction
5.2. How to use bigpharma oncology partnering deals
5.3. Bigpharma partnering company profiles

Abbott
Actavis
Alcon Labs
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Lundbeck
Menarini
Merck & Co
Merck – Serono
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Ratiopharm
Roche
Sanofi-Aventis
Schering Plough
Servier
Shire
Solvay
Takeda
Teva
UCB
Watson
Wyeth

Chapter 6 – Oncology dealmaking directory

6.1. Introduction
6.2. Company A-Z
6.3. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
6.4. By deal type
Asset and product purchase
Collaborative R&D
Co-development
Co-marketing
Co-promotion
Development
Distribution
Joint venture
Licensing
M&A
Manufacturing
Marketing
Promotion
Option
Research
Supply
6.5. By oncology type
Bladder
Breast
Brain
Cervical
Colorectal
Gastrointestinal
Head and neck
Kidney
Leukemia
Liver
Lung
Lymphoma
Melanoma
Multiple myeloma
Ovarian
Pancreatic
Prostate
Solid tumour
Broad focus
Diagnostics
Drug delivery

Chapter 7 – Oncology partnering resource center
7.1. Online oncology partnering
7.2. Oncology partnering events
7.3. Further reading on oncology dealmaking

Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example oncology partnering agreement

Figures in report

Figure 1: Components of the typical oncology deal structure
Figure 2: Discovery stage average payment terms
Figure 3: Average royalty rates payment terms
Figure 4: Oncology partnering since 2000
Figure 5: Most active oncology dealmakers 2003-2008
Figure 6: Bigpharma – top 50 – oncology deals 2003 to 2008
Figure 7: Inactive oncology dealmakers 2003-2008
Figure 8: Oncology partnering by stage of development since 2003
Figure 9: Oncology partnering by deal type since 2003
Figure 10: Oncology co-promotion deals since 2003
Figure 11: Oncology option deals since 2003
Figure 12: Oncology partnering by disease type from 2003
Figure 13: Trends in broad focus oncology partnering since 2003
Figure 14: Top oncology deals by value since 2000
Figure 15: Top 50 oncology deals signed by bigpharma value since 2000
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions
Figure 19: Oncology partnering between Daiichi Sankyo and ArQule, November 2008